Liquidia Corporation Shares Rise 7% Following Q3 Results and Litigation Settlement
Liquidia Corporation (LQDA) saw its stock price increase by over 7% on Tuesday, closing at $51.40. The upward movement follows the company's release of third-quarter financial results and the successful resolution of a long-standing legal dispute with United Therapeutics. The settlement addresses significant litigation that had previously created uncertainty for the commercial-stage biopharmaceutical firm. As a company focused on pulmonary arterial hypertension, the removal of this legal overhang is viewed as a positive development for its operational stability and market positioning.